During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

Aurobindo Pharma’s Dazublys, a trastuzumab biosimilar for HER2-positive cancers, gains EU approval, enhancing access to ...

Recurrence means that cancer has come back after initial treatment and a period during which it could not be detected. Even ...

Topline data were announced from a phase 3 trial evaluating bemarituzumab plus chemotherapy in individuals with gastric or gastroesophageal junction cancer with FGFR2b overexpression.

CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

US FDA clears Iksuda Therapeutics’ IND application for IKS014: New Castle, England Wednesday, July 2, 2025, 15:00 Hrs [IST] Iksuda Therapeutics, a clinical stage and UK-based bi ...

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new ...